CGTX - COGNITION THERAPEUTICS INC
IEX Last Trade
0.6751
0.009 1.348%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:31 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$0.67
0.01
1.37%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.84%
1 Month
59.21%
3 Months
56.14%
6 Months
-63.18%
1 Year
-61.88%
2 Year
-72.54%
Key data
Stock price
$0.68
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.39 - $2.92
52 WEEK CHANGE
-$65.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Lisa R. Ricciardi
Region: US
Website: cogrx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cogrx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cognition Therapeutics, Inc. engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease.
Recent news